Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
The companion Handbook on Humanitarian Access presents the normative framework pertaining to humanitarian access in situations of armed conflict, and therefore serves as a useful reference source for humanitarian practitioners on the normative framework.
This initial version of the Field Manual –... labeled Version 1.0 – was elaborated by Conflict Dynamics International in collaboration with the FDFA and the UN Office for the Coordination of Humanitarian Affairs (OCHA).
Development of the structured approach and guidance contained in this Manuel
involved a consultation process which included bilateral meetings with humanitarian organizations, regional consultation events and consultations during several field visits, including dedicated field missions
more
Analyse des politiques et des programmes : opportunités et défis pour l’UNFPAseptembre
An Independent Report
of the West Africa Commission on Drugs
(Mise à jour décembre 2014)
Lignes directrices.
Collection Avis et Rapports.